Application 215868
- Type
- NDA
- Sponsor
- EXELA PHARMA
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | MIDAZOLAM | SOLUTION;INTRAVENOUS | 50MG/50ML (1MG/ML) | No | No |
| 002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | MIDAZOLAM | SOLUTION;INTRAVENOUS | 100MG/100ML (1MG/ML) | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | MIDAZOLAM | 50MG/50ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | |
| N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | MIDAZOLAM | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2022-07-20 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | 8072bd15b7f6… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | 6a51e52b5d6a… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | 1c564ffb4f44… | |
| 2024-02-18 07:12 UTC | 2024-02 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | ea1830bbd6c7… | |
| 2023-12-20 04:57 UTC | 2023-12 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | a72a2bbeb626… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | 9b2671bbb829… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N215868-001 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 50MG/50ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | a67488948f0b… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N215868-002 | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | 100MG/100ML (1MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2022-07-20 | a67488948f0b… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Midazolam in Sodium Chloride | MIDAZOLAM | WG Critical Care, LLC. | f051776f-94c5-4e34-80ed-f45b9c36881e | 2026-05-14 | Boxed warning, Warnings, Adverse reactions | MIDAZOLAM |
| Midazolam | MIDAZOLAM | Henry Schein, Inc. | 3c2fd6ee-4ede-4ee4-8c05-34c93598f381 | 2025-10-31 | Boxed warning, Warnings, Adverse reactions | MIDAZOLAM |
| Midazolam | MIDAZOLAM | Henry Schein, Inc. | 78e28b13-414e-4c34-a42c-caf1c3ba1f54 | 2025-10-31 | Boxed warning, Warnings, Adverse reactions | MIDAZOLAM |
| Midazolam | MIDAZOLAM | Henry Schein, Inc. | 90f7b7f6-d0fd-40af-bbfa-70b152e3e27c | 2025-10-31 | Boxed warning, Warnings, Adverse reactions | MIDAZOLAM |
| MIDAZOLAM IN 0.8% SODIUM CHLORIDE | MIDAZOLAM IN 0.8% SODIUM CHLORIDE | B. Braun Medical Inc. | adfe8ece-496d-4118-9990-a1d44d0ac7d9 | 2025-10-15 | Boxed warning, Warnings, Adverse reactions | MIDAZOLAM IN 0.8% SODIUM CHLORIDE |
| Midazolam | MIDAZOLAM | Henry Schein, Inc. | 94e1342b-f597-44c0-b8fc-b753fde04cbe | 2025-06-26 | Boxed warning, Warnings, Adverse reactions | MIDAZOLAM |
| Midazolam | MIDAZOLAM | Civica, Inc. | f0c8b6cd-9efc-4344-9212-fbdd3b8e2f9b | 2024-12-26 | Boxed warning, Warnings, Adverse reactions | MIDAZOLAM |
| Midazolam | MIDAZOLAM | Hikma Pharmaceuticals USA Inc. | f8bb3427-c887-47b6-8042-8a21dc161c79 | 2024-12-17 | Boxed warning, Warnings, Adverse reactions | MIDAZOLAM |
| Midazolam | MIDAZOLAM | Hikma Pharmaceuticals USA Inc. | 8675cdb1-c7f5-40cf-b1e0-0960b7ab117b | 2024-04-10 | Boxed warning, Warnings, Adverse reactions | MIDAZOLAM |
| Midazolam | MIDAZOLAM | Hikma Pharmaceuticals USA Inc. | 575d8bf0-7af7-427c-a231-966e2a5e070d | 2024-04-09 | Boxed warning, Warnings, Adverse reactions | MIDAZOLAM |
| Midazolam | MIDAZOLAM | Hikma Pharmaceuticals USA Inc. | 51c8bfa4-5c78-4b7a-9ffb-8f00828acadc | 2024-03-29 | Boxed warning, Warnings, Adverse reactions | MIDAZOLAM |
| Midazolam | MIDAZOLAM | Micro Labs Limited | 9221894f-d840-46f2-a11c-6b71358d3b5b | 2023-08-24 | Boxed warning, Warnings, Adverse reactions | MIDAZOLAM |
| Nayzilam | MIDAZOLAM | UCB, Inc. | 2b29422e-54d5-4a49-8522-e9cf752368c3 | 2023-01-19 | Boxed warning, Warnings, Adverse reactions | MIDAZOLAM |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 51754-2130 | MIDAZOLAM HYDROCHLORIDE | MIDAZOLAM HYDROCHLORIDE | Exela Pharma Sciences, LLC | NDA | Current |
| 51754-2130 | MIDAZOLAM HYDROCHLORIDE | MIDAZOLAM HYDROCHLORIDE | Exela Pharma Sciences, LLC | NDA | Current |
| 51754-2131 | MIDAZOLAM HYDROCHLORIDE | MIDAZOLAM HYDROCHLORIDE | Exela Pharma Sciences, LLC | NDA | Current |
| 51754-2131 | MIDAZOLAM HYDROCHLORIDE | MIDAZOLAM HYDROCHLORIDE | Exela Pharma Sciences, LLC | NDA | Current |